🔗 Share this article US and UK Strike Tariff-Free Deal on Drugs. Stock image of drug shipments. The UK and US have hammered out a key commercial pact that will guarantee zero import taxes on British pharmaceutical products entering the American market. Agreement Details of the Pact As part of the deal, the UK has pledged to boost expenditure on pharmaceuticals through the NHS. This move ensures that import taxes on these vital exports will be held at nothing for a period of three years. This development comes after earlier threats to dramatically increase import taxes on branded drug imports, with increases mentioned as high as double the cost. "This arrangement between the UK bolsters the global environment for innovative medicines and establishes long-overdue balance to transatlantic medicine commerce," an announcement declared. Economic Impact Medicines constitute one of the UK's most significant exports to the US, which is easily the largest destination for large companies like GSK and AstraZeneca. Export figures reveal that in the year to the end of last September, the UK sold drugs totaling billions to the US. This figure made up nearly one-fifth of all goods exports in that span. "This guarantee secures employment, increases investment and paves the way for the UK to establish itself as a worldwide center for life sciences," a minister remarked. Detailed British Pledges The pact involves several notable pledges from the UK: Price Threshold Increase: The UK will lift the affordability limit at which it considers new medicines to be unaffordable by a quarter. Higher Drug Budget: There is a aim to increase total NHS spending on treatments from 0.3 percent of the national economy to 0.6% over the coming ten years. Payback Limit: The percentage pharmaceutical firms must pay back to the NHS to stay within budget will be limited at 15%. In the past, refunds topped 20%. Industry Background The deal comes amid a long-running dispute between the drug companies and the British authorities over medicine costs and NHS adoption. The disagreement were exacerbated by claims that US patients were charged a premium for the same drugs than people in the Britain and the EU. Recently, several major drug company projects in the UK have been paused or cancelled, while multi-billion-dollar investments have been announced toward American operations. The Science Minister stated that the NHS must invest a greater share on medicines, noting that its expenditure on drugs had decreased as a share of its total funding over the past decade.
Stock image of drug shipments. The UK and US have hammered out a key commercial pact that will guarantee zero import taxes on British pharmaceutical products entering the American market. Agreement Details of the Pact As part of the deal, the UK has pledged to boost expenditure on pharmaceuticals through the NHS. This move ensures that import taxes on these vital exports will be held at nothing for a period of three years. This development comes after earlier threats to dramatically increase import taxes on branded drug imports, with increases mentioned as high as double the cost. "This arrangement between the UK bolsters the global environment for innovative medicines and establishes long-overdue balance to transatlantic medicine commerce," an announcement declared. Economic Impact Medicines constitute one of the UK's most significant exports to the US, which is easily the largest destination for large companies like GSK and AstraZeneca. Export figures reveal that in the year to the end of last September, the UK sold drugs totaling billions to the US. This figure made up nearly one-fifth of all goods exports in that span. "This guarantee secures employment, increases investment and paves the way for the UK to establish itself as a worldwide center for life sciences," a minister remarked. Detailed British Pledges The pact involves several notable pledges from the UK: Price Threshold Increase: The UK will lift the affordability limit at which it considers new medicines to be unaffordable by a quarter. Higher Drug Budget: There is a aim to increase total NHS spending on treatments from 0.3 percent of the national economy to 0.6% over the coming ten years. Payback Limit: The percentage pharmaceutical firms must pay back to the NHS to stay within budget will be limited at 15%. In the past, refunds topped 20%. Industry Background The deal comes amid a long-running dispute between the drug companies and the British authorities over medicine costs and NHS adoption. The disagreement were exacerbated by claims that US patients were charged a premium for the same drugs than people in the Britain and the EU. Recently, several major drug company projects in the UK have been paused or cancelled, while multi-billion-dollar investments have been announced toward American operations. The Science Minister stated that the NHS must invest a greater share on medicines, noting that its expenditure on drugs had decreased as a share of its total funding over the past decade.